Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment.
CONCLUSION: Peak anti-Xa levels provided by enoxaparin 20 mg were lower than the desired range for thromboprophylaxis in comparison to enoxaparin 30 mg.
TRIAL REGISTRATION: The trial was retrospectively registered on ClinicalTrials.gov identifier: NCT03158792 . Registered: May 18, 2017.
PMID: 31064405 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
More News: Bleeding | Clinical Trials | Drugs & Pharmacology | Lovenox | Thrombocytopenia | Thrombosis | Toxicology